<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of polycythemia vera</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of polycythemia vera</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of polycythemia vera</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polycythemia vera (PV, polycythemia rubra vera, maladie de Vaquez) is one of the chronic myeloproliferative neoplasms (MPNs), which are collectively characterized by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. PV is distinguished clinically from the other MPNs by the presence of an elevated red blood cell mass. However, an increased red blood cell mass alone is insufficient to establish the diagnosis, since this is also observed in conditions associated with chronic hypoxia and with erythropoietin-secreting tumors  (<a class="graphic graphic_table graphicRef76036" href="/d/graphic/76036.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p>The clinical manifestations and diagnosis of PV will be discussed here. The prognosis and treatment of PV and the overall approach to the patient with polycythemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PV occurs in all populations, and all ages, including early adulthood and occasionally in children and adolescents [<a href="#rid1">1-3</a>]. The median age at diagnosis is approximately 60 years [<a href="#rid4">4,5</a>]. Approximately one-quarter of cases present before age 50 years and one-tenth before age 40 years.</p><p>The incidence of PV in Olmsted County, Minnesota, during the period from 1935 through 1989, was estimated to be 1.9/100,000 per year, approximately one-half that for multiple myeloma in the same population [<a href="#rid6">6</a>]. The incidence of PV is slightly higher in men than women (2.8 versus 1.3 cases/100,000 per year) and is highest for men aged 70 to 79 years (24 cases/100,000 persons per year) [<a href="#rid6">6</a>]. The incidence is lower in Japan than in the United States and Europe [<a href="#rid7">7</a>].</p><p>While there is no known familial disposition to PV, rare families have been described in which multiple members develop myeloproliferative neoplasms, including PV [<a href="#rid8">8</a>]. Studies of these families suggest the presence of an autosomal dominant mutation that may predispose to acquisition of a secondary somatic mutation such as a <em>JAK2</em> mutation.</p><p>Exposure to ionizing radiation and toxins (eg, benzene) has been suggested as a risk factor, although the vast majority of patients presenting with PV have no evidence of risk exposure.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H942470695"><span class="h2">Overview of signs and symptoms</span><span class="headingEndMark"> — </span>Most patients with PV are discovered incidentally when an elevated hemoglobin or hematocrit is noted on a complete blood count obtained for some other reason. Others present with disease-related symptoms (eg, headache, dizziness, visual disturbances, pruritus, early satiety) or complications (eg, thrombosis, bleeding)  (<a class="graphic graphic_table graphicRef54453" href="/d/graphic/54453.html" rel="external">table 2</a>).</p><p>An analysis of 1545 patients with World Health Organization (WHO)-defined PV collected by the International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) noted the following findings prior to or at diagnosis [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin – median 18.4 g/dL, range 15.1 to 26.5 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Hematocrit – median 55 percent, range 36 to 78 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocyte count – median 10,400/microL, range 3000 to 172,000/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count – median 466,000/microL, range 70 to 2,370,000/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase – 50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – 46 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable spleen – 36 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus – 36 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Vasomotor symptoms (eg, erythromelalgia) – 29 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial thrombosis – 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Venous thrombosis – 7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Major hemorrhage – 4 percent</p><p></p><p>Other physical findings that suggest a diagnosis of PV include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Injection of the conjunctival small vessels and/or engorgement of the veins of the optic fundus</p><p class="bulletIndent1"><span class="glyph">●</span>Facial plethora (ruddy cyanosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly in a minority of cases</p><p class="bulletIndent1"><span class="glyph">●</span>Excoriation of the skin, which might be extensive, suggesting the presence of severe pruritus, a common complaint in PV</p><p class="bulletIndent1"><span class="glyph">●</span>Stigmata of a prior arterial or venous thrombotic event (eg, stroke, deep vein thrombosis, superficial thrombophlebitis)</p><p class="bulletIndent1"><span class="glyph">●</span>Gouty arthritis and tophi</p><p></p><p>Patient questionnaires have also reported mild nonspecific complaints in the majority of patients including fatigue, early satiety, abdominal discomfort, headache, difficulty concentrating, dizziness, numbness, insomnia, sad mood, sexual problems, excessive sweating, itching, and impaired quality of life [<a href="#rid9">9,10</a>]. In one study, a more severe total symptom burden similar to that of patients with primary myelofibrosis was seen in patients with splenomegaly and those requiring phlebotomy and/or <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid11">11</a>]. These results illustrate the variability of total symptom burden and suggest that splenomegaly is a marker of more severely symptomatic disease.</p><p class="headingAnchor" id="H6"><span class="h2">Pruritus</span><span class="headingEndMark"> — </span>Pruritus following a warm bath or shower (aquagenic pruritus) is characterized by strong sensations in the skin following contact with water without visible changes in the skin [<a href="#rid12">12-14</a>]. Aquagenic pruritus is often the chief complaint of a patient with PV, has been described as "unbearable" in 15 percent of those with this symptom, and may be present for many years before the diagnosis of PV is made.</p><p>In a questionnaire completed in 441 patients with PV, 301 (68 percent) of which had aquagenic pruritus, the following information was obtained [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms were described as itching, tickling, stinging, or burning in 72, 21, 31, and 18 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Almost one-half of the respondents noted that warm water caused stronger symptoms than cold water, while 38 percent noted no difference between the two.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 78 percent, symptom onset was within less than 10 minutes after water contact.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most commonly involved symptomatic areas were the chest, back, medial side of the arms, and ventral side of the legs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aquagenic pruritus was present, on average, approximately three years before the diagnosis of PV was made and was the basis for suspecting the diagnosis of PV in 15 percent.</p><p></p><p>This complaint was present in 31 percent of patients with PV seen at the Mayo Clinic, where, for unexplained reasons, it was associated with a significantly lower incidence of arterial thrombosis [<a href="#rid15">15</a>].</p><p>The cause of pruritus in PV is unclear. It has been suggested that mast cell degranulation, with release of histamine, fibrinolytic factors, prostaglandins, or interleukin-31, may play a role [<a href="#rid16">16-19</a>]. An alternative hypothesis is that the release of adenosine diphosphate from red cells or catecholamines from adrenergic vasoconstrictor nerves when the skin is cooled down might cause platelet aggregation in skin vessels, with local production of pruritogenic factors, such as prostaglandins [<a href="#rid18">18</a>]. The observation that <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> can relieve pruritus in at least some patients is compatible with an important role for prostaglandins [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Erythromelalgia</span><span class="headingEndMark"> — </span>Erythromelalgia, or burning pain in the feet or hands accompanied by erythema, pallor, or cyanosis, in the presence of palpable pulses  (<a class="graphic graphic_picture graphicRef81121" href="/d/graphic/81121.html" rel="external">picture 1</a>) was seen in 29 percent of patients with WHO-defined PV in one series [<a href="#rid5">5</a>]. Erythromelalgia and the associated symptom of acral paresthesias, both of which can be considered to be forms of dysesthesia, are considered to be pathognomonic microvascular thrombotic complications in PV and essential thrombocythemia and are associated with platelet counts usually &gt;400,000/microL [<a href="#rid20">20,21</a>]. These symptoms respond dramatically to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in low doses or to reduction of the platelet count to normal with low-dose myelosuppressive agents [<a href="#rid20">20-22</a>]; they may be related to abnormal arachidonic acid metabolism in PV platelets [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Vasomotor symptoms'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Thrombosis and hemorrhage</span><span class="headingEndMark"> — </span>Patients with PV have an increased risk of thrombosis (eg, cerebrovascular event, myocardial infarction, superficial thrombophlebitis, deep vein thrombosis, pulmonary embolus) and hemorrhage. In a large international study, an arterial thrombotic complication, venous thrombosis, or major hemorrhage was noted prior to or at the time of diagnosis in 16, 7, and 4 percent of patients with PV as defined by the WHO [<a href="#rid5">5</a>].</p><p>Although the mechanisms involved in this hypercoagulable state are unclear, abnormalities in blood viscosity, platelets, and leukocytes have been implicated [<a href="#rid23">23</a>]. Major thrombotic events can occur in patients who otherwise have few clinical and laboratory features of PV. Examples include the Budd-Chiari syndrome and portal, splenic, or mesenteric vein thrombosis [<a href="#rid24">24</a>], in whom the ensuing portal hypertension and hypersplenism may mask the increase in blood cell counts [<a href="#rid25">25-30</a>]. PV should be suspected in patients with these diagnoses, particularly women under the age of 45. (See  <a class="medical medical_review" href="/d/html/3624.html" rel="external">"Etiology of the Budd-Chiari syndrome", section on 'Myeloproliferative disorders'</a>.)</p><p>In some patients with PV and platelet counts &gt;1 million/microL, acquired von Willebrand disease may be present, likely due to increased binding of large von Willebrand factor multimers to the platelets and their removal from the plasma. Such patients may have increased bleeding, especially when treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.)</p><p class="headingAnchor" id="H13560194"><span class="h2">Transient visual disturbance</span><span class="headingEndMark"> — </span>Transient visual disturbances (eg, transient ocular blindness [amaurosis fugax], scintillating scotomata, ophthalmic migraine) can occur in PV, similar to those seen in patients with essential thrombocythemia [<a href="#rid31">31</a>].</p><p>In one study of 374 patients with PV, 53 presented with visual disturbance as an initial symptom [<a href="#rid32">32</a>]. <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">Fluorescein</a> angiography in the 21 patients who presented with transient ocular blindness indicated significantly delayed choroidal and retinal blood flow when compared with results obtained in 30 non-PV control patients. On multivariate analysis, an increased hematocrit was the only parameter significantly correlated with reduced choroidal and retinal blood flow. Treatment of these 21 patients with phlebotomy and <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> to reduce their hematocrit to less than 50 percent resulted in significant improvement in choroidal and retinal blood flow and a reduction in the subsequent incidence of transient blindness. (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia", section on 'Vasomotor symptoms'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Gastrointestinal complaints are common in PV, with a high incidence of epigastric distress, history of peptic ulcer disease, and gastroduodenal erosions on upper endoscopy [<a href="#rid33">33</a>]. These have been attributed to alterations in gastric mucosal blood flow due to altered blood viscosity, and/or increased histamine release from tissue basophils, although one study has indicated a high incidence of positivity for infection with Helicobacter pylori [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H11"><span class="h1">PATHOLOGIC AND LABORATORY FEATURES</span><span class="headingEndMark"> — </span>Most patients with PV are discovered incidentally when an elevated hemoglobin or hematocrit is noted on a complete blood count obtained for some other reason. In one series of patients with World Health Organization (WHO)-defined PV, the following laboratory findings were noted [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin &gt;18.5 g/dL – 73 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Total white blood cell (WBC) count &gt;10,500/microL – 49 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &gt;450,000/microL – 53 percent; platelet count &gt;1 million/microL – 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Leukoerythroblastic blood smear – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase – 50 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2</em> mutation positivity – 98 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal karyotype – 12 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Subnormal serum erythropoietin level – 81 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Endogenous erythroid colony formation – 73 percent</p><p></p><p>These findings are described in more detail in the following sections.</p><p class="headingAnchor" id="H926360239"><span class="h2">Peripheral blood smear</span><span class="headingEndMark"> — </span>The findings in the peripheral blood differ depending upon the stage of disease at the time of diagnosis.</p><p>In the prepolycythemic and overt polycythemic stages, the peripheral blood usually has an excess of normochromic, normocytic red blood cells. Hypochromic, microcytic red cells may be present if there is concomitant iron deficiency. Thrombocytosis is common (median platelet count 466,000/microL, range 70 to 2,370,000/microL) and approximately 15 percent of cases may mimic essential thrombocytosis [<a href="#rid5">5</a>]. Leukocytosis is also seen in the absence of fever or infection (median WBC count 10,400/microL, range 3000 to 172,000/microL). However, the total WBC count may not accurately reflect disease activity, since neutrophils and not lymphocytes or monocytes are increased in PV. While immature cells may be seen, blasts are not a characteristic feature.</p><p>In contrast, a leukoerythroblastic picture develops in the postpolycythemic myelofibrosis stage with teardrop-shaped red blood cells (dacryocytes), poikilocytosis, and circulating nucleated red cells. (See  <a class="medical medical_review" href="/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a>.)</p><p class="headingAnchor" id="H926361313"><span class="h2">Bone marrow aspiration and biopsy</span></p><p class="headingAnchor" id="H785906116"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>Bone marrow biopsy classically shows hypercellularity for age and trilineage growth with prominent erythroid, granulocytic, and megakaryocytic proliferation [<a href="#rid34">34</a>]. The findings on bone marrow examination change as the disease evolves from a prodromal prepolycythemia phase with borderline to mild erythrocytosis to an overt polycythemic phase with increased red cell mass to a "spent" or postpolycythemic myelofibrosis with cytopenias, ineffective erythropoiesis, fibrosis, extramedullary hematopoiesis, and hypersplenism.</p><p>Although the Polycythemia Vera Study Group (PVSG) did not include specific bone marrow findings as either major or minor criteria for diagnosis, 281 pretreatment bone marrow biopsies were obtained in the first PVSG study and the following observations were noted [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common abnormality was the absence of stainable iron in 94 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cellularity varied from 36 to 100 percent (mean 82 percent, normal 35 to 50 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>The numbers of megakaryocytes and amount of reticulin were variable, although both were generally increased</p><p></p><p>Bone marrow biopsy findings are a major criterion in the WHO diagnostic criteria. In a study of 526 subjects who met the WHO criteria for the diagnosis of PV, 74 (14 percent) displayed minor (grade 1) reticulin fibrosis on their initial bone marrow examination, and only two showed higher grade fibrosis [<a href="#rid36">36</a>]. Presenting clinical and laboratory characteristics, including <em>JAK2</em> V617F allele burdens, between patients with and without fibrosis were generally similar, although palpable splenomegaly was significantly more common in those with fibrosis. While there was no difference between the two patient groups in terms of overall or leukemia-free survival, those with fibrosis were significantly more prone to develop post-PV myelofibrosis (2.2 versus 0.8 per 100 patient-years) and significantly less prone to experience thrombosis during their clinical course (1.1 versus 2.7 per 100 patient-years).</p><p class="headingAnchor" id="H926361387"><span class="h3">Clonal markers</span><span class="headingEndMark"> — </span>Bone marrow examination can also be used to identify clonal markers that have been associated with PV, such as karyotypic changes and, in women, X-linked inactivation patterns or restriction length polymorphisms. These clonal features initially helped to establish the malignant character of PV but are not incorporated into diagnostic criteria.</p><p>Deletion of the long arm of chromosome 20, trisomy for chromosomes 8 or 9, or loss of heterozygosity on the short arm of chromosome 9 are found in up to 30 percent of previously untreated patients with PV [<a href="#rid37">37-42</a>]. Of interest, chromosome 9p24 houses the <em>JAK2</em> gene, which carries a somatic point mutation in virtually all patients with PV (see <a class="local">'JAK2 mutations'</a> below).</p><p class="headingAnchor" id="H3008612693"><span class="h3">JAK2 mutations</span><span class="headingEndMark"> — </span>When sensitive quantitative assays are employed, 95 to 100 percent of patients with PV have a <em>JAK2</em> (Janus kinase 2) mutation involving either exon 14 or 12 [<a href="#rid5">5,43-48</a>].</p><p class="headingAnchor" id="H3008612881"><span class="h4">Exon 14 mutation</span><span class="headingEndMark"> — </span>In multiple studies, 95 to 97 percent of patients with PV have the V617F mutation in exon 14 of the <em>JAK2</em> gene, which is absent in normal subjects as well as those with secondary polycythemia. Thus, this mutation, when present, enables one to distinguish patients with PV from those with secondary polycythemia [<a href="#rid49">49-51</a>]. The finding of the <em>JAK2</em> V617F mutation is not specific for PV, since it is also present in a substantial proportion of patients with essential thrombocythemia (ET) as well as primary myelofibrosis. (See  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'JAK2 mutations'</a>.)</p><p>In a study of 63 patients with PV evaluated at the Mayo Clinic, the <em>JAK2</em> mutation was present in 58 (92 percent); 45 and 13 were heterozygous or homozygous for this mutation in peripheral blood granulocytes, respectively [<a href="#rid52">52</a>]. A comparison between the heterozygotes and homozygotes did not reveal significant differences with regard to duration of disease or incidence of thrombosis or bleeding. However, homozygotes had higher hemoglobin levels, a greater incidence of pruritus, a higher rate of fibrotic transformation, and higher PRV-1 transcript levels in peripheral blood granulocytes than the heterozygotes.</p><p>In other studies, high levels of this mutation were found to correlate with higher granulocyte counts [<a href="#rid53">53-55</a>], potentially linking this mutation to the higher incidence of thrombosis seen in PV patients with leukocytosis [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis"</a>.)</p><p>A higher rate of homozygous <em>JAK2</em> V617F mutations may be present when testing is performed in erythroid burst-forming units (BFU-Es) rather than peripheral blood granulocytes. In one report using this technology, homozygous <em>JAK2</em> V617F mutations were found in all 17 patients with PV, both patients with ET after polycythemic transformation, and none of the 15 patients with ET alone [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H3008613037"><span class="h4">Exon 12 mutations</span><span class="headingEndMark"> — </span>In one study, four different mutations in exon 12 of the <em>JAK2</em> gene were found in 10 of 11 patients clinically diagnosed as having PV who had tested negative for the exon 14 V617F mutation [<a href="#rid43">43</a>]. The mutations were frequently present at low levels in granulocyte DNA but were readily identifiable in clonally derived erythropoietin-independent erythroid colonies. When transduced into BaF3/EpoR cells, all four <em>JAK2</em> exon 12 mutations caused growth factor hypersensitivity and activated biochemical pathways associated with erythropoietin signaling.</p><p>In a second report of 114 patients fulfilling the PVSG diagnostic criteria for PV, 111 ultimately tested positive for the exon 14 V617F mutation (97 percent); a <em>JAK2</em> exon 12 mutation was present in the remaining three subjects (3 percent), suggesting that either an exon 14 or 12 <em>JAK2</em> mutation is present in virtually all patients with PV [<a href="#rid48">48,58,59</a>].</p><p>A third study reported on 106 patients with PV and exon 12 mutations, in which 17 different mutations were identified [<a href="#rid60">60</a>]. Irrespective of the mutation, two-thirds had isolated erythrocytosis, with the remainder having erythrocytosis plus leukocytosis and/or thrombocytosis. The panmyelosis observed in the bone marrow of most patients with PV is typically absent in those with exon 12 mutations. Compared with <em>JAK2</em> V617F-positive PV patients, those with exon 12 mutations had similar incidences of thrombosis, myelofibrosis, leukemia, and death [<a href="#rid47">47,60</a>].</p><p>Exon 12 mutations were not found in granulocyte DNA in any of 55 patients with V617F-positive PV, any of 25 patients with V617F-negative ET, or any of 12 patients with V617F-negative primary myelofibrosis [<a href="#rid43">43</a>]. However, exon 12 mutations have been found in patients with myeloproliferative disorders presenting with isolated erythrocytosis, familial PV, and, in two cases, splanchnic vein thrombosis [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H926361548"><span class="h2">Serum erythropoietin</span><span class="headingEndMark"> — </span>Patients with PV usually have low serum erythropoietin (EPO) concentrations [<a href="#rid63">63-67</a>]. While low EPO levels are highly specific for PV, levels above normal are unusual and suggest secondary erythrocytosis, with a specificity of 98 percent [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a>.)</p><p>In two studies, for example, serum EPO levels in 42 patients with PV were compared with control subjects with other causes of polycythemia (eg, hypoxia) [<a href="#rid63">63,68</a>]. The sensitivity and specificity of serum EPO levels below the reference range of normal for the diagnosis of PV (using the polycythemia vera study group criteria as the gold standard) were 64 and 92 to 99 percent, respectively. The sensitivity increased to 72 percent in patients who were tested on two occasions, as low serum EPO values were noted on a repeat study in some patients with normal levels on the initial examination. The serum EPO concentration remained low even when the red cell mass was normalized following phlebotomy. Accordingly, most of the newer diagnostic criteria for PV have included a low serum EPO level. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p class="headingAnchor" id="H3008611858"><span class="h2">Increased red blood cell mass</span><span class="headingEndMark"> — </span>Red blood cell mass (RCM) can be measured directly using isotope dilution methodology, but this technique is no longer available in many locations. Instead, most clinicians use the hemoglobin concentration to estimate the RCM such that a hemoglobin &gt;18.5 g/dL in men or &gt;16.5 g/dL in women is considered a measure of elevated RCM.</p><p>Direct determination of the RCM is prone to error and has suboptimal sensitivity [<a href="#rid69">69,70</a>]. In the original PVSG diagnostic criteria, RCM cutoffs (RCM, &gt;36 mL/kg in men and &gt;32 mL/kg in women) were set at approximately 10 to 20 percent above the upper limits of normal and were deliberately chosen to reject patients with relatively early or inactive disease. However, this specific PVSG research protocol requirement did not apply to the general clinical setting, in which it may be preferable to include a broader range of patients. As a result, two revised approaches have been proposed:</p><p>The International Council for Standardization in Hematology (ICSH) recommended that blood volumes be calculated in terms of body surface area, since normalization of blood volume to total body weight is less accurate in obese patients [<a href="#rid71">71</a>]. Historically, RCM, normalized to body surface area, was considered elevated if it was more than 25 percent above the mean expected value [<a href="#rid72">72</a>].</p><p>It has been our experience, and that of others, that the majority of female patients with a hemoglobin concentration &gt;16.5 g/dL (or hematocrit [Hct] above 50 percent) and all male patients with a hemoglobin concentration &gt;18.5 g/dL (or Hct above 56 percent) have an increased RCM [<a href="#rid69">69,73</a>]. Slightly different cutoff values were found in reports from Belgium and Sweden (Hct greater than 55 [<a href="#rid74">74</a>] or 60 percent [<a href="#rid75">75</a>] in women and greater than 60 percent in men [<a href="#rid74">74,75</a>]).</p><p class="headingAnchor" id="H926361805"><span class="h2">Endogenous erythroid colony formation</span><span class="headingEndMark"> — </span>A common feature of several myeloproliferative neoplasms is the demonstration, using in vitro culture techniques, of the formation of erythroid colonies in the absence of added (exogenous) erythropoietin (ie, endogenous erythroid colonies [EEC]). However, the measurement of EEC is not a standard test and is available only in a limited number of research laboratories that are especially interested in PV and hematopoiesis.</p><p>The presence of EEC strongly supports the diagnosis of PV if other criteria are present. One study, for example, evaluated EEC formation in 89 patients with various forms of polycythemia [<a href="#rid76">76</a>]. EEC formation was found in 100 percent of PV patients with no prior cytotoxic chemotherapy, 50 percent of PV patients with prior cytotoxic therapy, and in no patient with secondary polycythemia.</p><p>Thus, in polycythemic patients who have not had prior cytotoxic chemotherapy, the sensitivity and specificity of EEC formation for the diagnosis of PV is approximately 100 percent. This observation has been confirmed in other series [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3008611485"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>PV should be suspected in any patient with an increased red blood cell mass or increased hemoglobin/hematocrit and an arterial oxygen saturation &gt;92 percent. To be considered for the diagnosis, men should have a hemoglobin level of at least 16.5 g/dL or a hematocrit level of ≥49 percent, and women should have a hemoglobin level of at least 16 g/dL or a hematocrit level of ≥48 percent. PV should also be suspected in patients with the Budd-Chiari syndrome and portal, splenic, or mesenteric vein thrombosis, particularly women under the age of 45. In this setting, the ensuing portal hypertension and hypersplenism may mask the increase in blood cell counts. Additional evidence suggesting the diagnosis of PV includes the following (see <a class="local">'Clinical presentation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytosis and/or leukocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombotic complications</p><p class="bulletIndent1"><span class="glyph">●</span>Erythromelalgia or aquagenic pruritus</p><p class="bulletIndent1"><span class="glyph">●</span>Microvascular symptoms (eg, headaches, paresthesias)</p><p></p><p class="headingAnchor" id="H1015008585"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of a patient with suspected PV depends at least partially upon the initial presentation and whether the patient has asymptomatic, isolated erythrocytosis or has other signs/symptoms of a myeloproliferative disorder (eg, elevated white cell or platelet count)  (<a class="graphic graphic_algorithm graphicRef102385" href="/d/graphic/102385.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the only indication of PV is an elevated hemoglobin concentration or hematocrit, a complete blood count should be repeated. Further testing is unnecessary if the hemoglobin/hematocrit returns to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the hemoglobin/hematocrit remains elevated or if the patient has other signs/symptoms of a myeloproliferative disorder, the evaluation should include a serum erythropoietin (EPO) level and peripheral blood mutation screening for <em>JAK2</em> V617F. (See <a class="local">'JAK2 mutations'</a> above and <a class="local">'Serum erythropoietin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a normal or elevated EPO level and no <em>JAK2</em> V617F mutation do not have PV. Further evaluation is directed at other causes of polycythemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a sustained elevation of hemoglobin/hematocrit, a subnormal serum EPO level, and a <em>JAK2</em> V617F mutation meet the diagnostic criteria for PV. A bone marrow aspiration and biopsy is not required in such patients unless there is reason to suspect disease evolution (eg, leukoerythroblastic blood smear).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a subnormal serum EPO level who do not have a <em>JAK2</em> V617F mutation should have peripheral blood mutation screening for exon 12 mutations. Identification of an exon 12 mutation in this setting confirms PV. If an exon 12 mutation is not identified, a bone marrow aspiration and biopsy should be performed. (See <a class="local">'Exon 12 mutations'</a> above and <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum EPO levels should be repeated in patients with a single normal test; the second value will be low in more than one-quarter of these patients [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with nondiagnostic bone marrow studies and/or absence of a <em>JAK2</em> mutation should have repeat measurement of the hemoglobin or hematocrit and serum EPO concentrations in three months. A diagnosis other than PV should be entertained in such patients.</p><p></p><p class="headingAnchor" id="H20383514"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnostic criteria for PV have evolved over the years. We generally agree with and use the World Health Organization (WHO) criteria  (<a class="graphic graphic_table graphicRef110224" href="/d/graphic/110224.html" rel="external">table 3</a>). (See <a class="local">'WHO criteria'</a> below.)</p><p>Diagnostic criteria for PV require the following be met:</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of an increased red blood cell mass as determined either by blood volume studies or the presence of a very much increased hemoglobin concentration or elevated hematocrit</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disorders causing secondary erythrocytosis are absent, including hypoxia, familial polycythemic disorders, high-affinity hemoglobins, truncated EPO receptor, and inappropriate EPO production by tumor</p><p></p><p>Some patients with PV may not fulfill the WHO criterion of an increased hemoglobin/hematocrit or increased red cell mass because of a prior bleeding episode. This has been called "bled-down" PV if they otherwise meet the major and minor criteria for this diagnosis. Such patients may be incorrectly diagnosed as having iron deficiency or essential thrombocythemia since their high platelet counts, low red blood cell indices, and low serum ferritin concentrations may be the most striking features.</p><p>When blood volume measurements are either unavailable or not performed, some patients with a simultaneous increase in red cell mass and plasma volume due to an increase in splenic size may not have an elevated hemoglobin/hematocrit [<a href="#rid79">79</a>]. Such patients have been termed "masked" PV [<a href="#rid80">80-82</a>].</p><p>Patients with the Budd-Chiari syndrome often present without classical features of PV and may not fulfill the WHO criteria. The diagnosis can be suspected because many are positive for the <em>JAK2</em> mutation. (See  <a class="medical medical_review" href="/d/html/3624.html" rel="external">"Etiology of the Budd-Chiari syndrome", section on 'Myeloproliferative disorders'</a>.)</p><p class="headingAnchor" id="H20383528"><span class="h3">WHO criteria</span><span class="headingEndMark"> — </span>We generally use the 2016 WHO criteria for the diagnosis of PV, which includes the following  (<a class="graphic graphic_table graphicRef110224" href="/d/graphic/110224.html" rel="external">table 3</a>) [<a href="#rid83">83-88</a>]:</p><p>Major criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Increased hemoglobin level (&gt;16.5 g/dL in men or &gt;16.0 g/dL in women), hematocrit (&gt;49 percent in men or &gt;48 percent in women), or other evidence of increased red cell volume</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2 </em>V617F or <em>JAK2</em> exon 12 mutation</p><p></p><p>Minor criterion</p><p class="bulletIndent1"><span class="glyph">●</span>Serum erythropoietin level below the reference range for normal</p><p></p><p>The diagnosis of PV requires the presence of all three major criteria or the presence of the first two major criteria together with the minor criterion. These diagnostic criteria should be applied only to patients who have undergone the appropriate diagnostic evaluation to exclude secondary causes of polycythemia. The second major criterion may not be required in cases with sustained absolute erythrocytosis (hemoglobin &gt;18.5 g/dL or hematocrit &gt;55.5 percent in men; hemoglobin &gt;16.5 g/dL or hematocrit &gt;49.5 percent in women) if the third major criterion and the minor criterion are present. While this may permit the avoidance of a bone marrow evaluation for diagnostic purposes in some patients, the detection of myelofibrosis in the bone marrow at the time of diagnosis has prognostic value. (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a> and  <a class="medical medical_review" href="/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3380557"><span class="h3">British Committee for Standards in Hematology criteria</span><span class="headingEndMark"> — </span>Criteria for the diagnosis of PV according to the British Committee for Standards in Hematology are similar to those of the WHO criteria, with the exception that they are based upon an elevated hematocrit (&gt;52 percent in men, &gt;48 percent in women), rather than an elevated hemoglobin [<a href="#rid89">89,90</a>].</p><p class="headingAnchor" id="H20383870"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnostic possibilities in a patient who has fulfilled the diagnostic criteria for PV are vanishingly small and are likely confined to patients with one of the other <em>JAK2</em> mutation-positive myeloproliferative neoplasms (ie, essential thrombocythemia, primary myelofibrosis) who have an unrelated secondary cause for polycythemia  (<a class="graphic graphic_table graphicRef76036" href="/d/graphic/76036.html" rel="external">table 1</a>). (See <a class="local">'Secondary polycythemia'</a> below.)</p><p class="headingAnchor" id="H785906547"><span class="h2">Essential thrombocythemia</span><span class="headingEndMark"> — </span>When blood volume measurements are either unavailable or not performed, some patients with a simultaneous increase in red cell mass and plasma volume due to an increase in splenic size may not have an elevated hemoglobin/hematocrit [<a href="#rid79">79</a>]. Such patients have been termed "masked" PV if they otherwise meet the major and minor criteria for the diagnosis of PV [<a href="#rid80">80-82</a>].</p><p>Distinguishing patients with masked PV from those with essential thrombocythemia may be difficult  (<a class="graphic graphic_table graphicRef110225" href="/d/graphic/110225.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/4491.html" rel="external">"Clinical manifestations, pathogenesis, and diagnosis of essential thrombocythemia"</a>.)</p><p>A comparison of hematocrit or hemoglobin values in 257 patients with WHO-defined PV, 140 patients with masked PV, and 397 patients with essential thrombocythemia (ET) has suggested that the best cut-offs to distinguish masked PV from ET are the following [<a href="#rid82">82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For hemoglobin – &gt;16.5 g/dL in men and &gt;16.0 g/dL in women</p><p class="bulletIndent1"><span class="glyph">●</span>For hematocrit – &gt;49 percent in men and &gt;48 percent in women</p><p></p><p>The differential diagnosis for a patient with polycythemia but without the other major or minor Polycythemia Vera Study Group (PVSG), World Health Organization (WHO), or British Committee for Standards in Hematology (BCSH) criteria is discussed separately. (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a>.)</p><p class="headingAnchor" id="H785906633"><span class="h2">EPO receptor mutations</span><span class="headingEndMark"> — </span>A rare disorder that can mimic the basic findings of PV (ie, increased RCM with low serum erythropoietin [EPO]) is an activating mutation in the EPO receptor [<a href="#rid91">91-93</a>]. Patients with this disorder may also have endogenous erythroid colony formation [<a href="#rid76">76</a>]. However, colony growth in these patients can be distinguished from true PV because the colonies demonstrate in vitro EPO hypersensitivity rather than EPO independence [<a href="#rid91">91-93</a>]. A positive family history, early age at disease onset, and the lack of PV-associated clinical findings should provide adequate information to distinguish this familial disorder from PV.</p><p class="headingAnchor" id="H926360522"><span class="h2">Secondary polycythemia</span><span class="headingEndMark"> — </span>Because secondary causes of an elevated red cell mass (RCM) are much more common than PV, the diagnostic criteria should only be applied to populations in which other causes have been excluded. It has been estimated that the practicing hematologist sees 10 cases of relative or secondary polycythemia for every new patient with PV [<a href="#rid4">4</a>].</p><p>Since splenomegaly, leukocytosis, and thrombocytosis are common to all of the chronic myeloproliferative neoplasms  (<a class="graphic graphic_table graphicRef110239" href="/d/graphic/110239.html" rel="external">table 5</a>), a patient with chronic myeloid leukemia, essential thrombocythemia, or primary myelofibrosis who has an elevated hematocrit for another reason (eg, hypoxia, smoking) may be falsely diagnosed as having PV. This is an important distinction clinically because each of these disorders is treated in a different manner.</p><p class="headingAnchor" id="H3539143368"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116776.html" rel="external">"Society guideline links: Myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H364696711"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86713.html" rel="external">"Patient education: Polycythemia vera (PV) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by autonomous overproduction of red blood cells (RBCs) that is clinically manifested by elevated hemoglobin (Hb)/hematocrit (Hct), with or without an elevated white blood cell (WBC) and/or platelet count. PV can evolve into myelofibrosis or acute myeloid leukemia (AML).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – The most prominent symptoms of PV  (<a class="graphic graphic_table graphicRef54453" href="/d/graphic/54453.html" rel="external">table 2</a>) are related to increased blood viscosity and may include venous or arterial thrombosis (eg, deep vein thrombosis, myocardial infarction or ischemia, cerebrovascular accident), pruritus, erythromelalgia (ie, burning pain in hands or feet  (<a class="graphic graphic_picture graphicRef81121" href="/d/graphic/81121.html" rel="external">picture 1</a>)), facial plethora, visual disturbance, and/or headache. Other patients are detected by isolated laboratory abnormalities. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Evaluation of suspected PV includes  (<a class="graphic graphic_algorithm graphicRef102385" href="/d/graphic/102385.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History of thromboembolic or cardiovascular events, constitutional symptoms (fever, sweats, weight loss), pruritus, erythromelalgia, cardiovascular risk factors, abdominal fullness and examination for splenomegaly, thromboses, or bruising.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Laboratory studies include (see <a class="local">'Pathologic and laboratory features'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count (CBC) with differential count</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Blood smear </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testing for <em>JAK2</em> V617F in blood</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum erythropoietin (EPO)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow examination</strong> – Microscopy and cytogenetics. (See <a class="local">'Bone marrow aspiration and biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – PV should be suspected in a patient with increased Hb/Hct with adequate arterial oxygen saturation, especially if accompanied by thromboembolic events, splenomegaly, or constitutional symptoms  (<a class="graphic graphic_algorithm graphicRef102385" href="/d/graphic/102385.html" rel="external">algorithm 1</a>). (See <a class="local">'When to suspect the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis of PV requires all three major criteria <strong>or</strong> the first two major criteria plus the minor criterion  (<a class="graphic graphic_table graphicRef110224" href="/d/graphic/110224.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Major criteria</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Increased RBC mass</strong> – Elevated Hb (&gt;16.5 g/dL in men or &gt;16.0 g/dL in women) or elevated Hct (49 percent in men, &gt;48 percent in women).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Bone marrow biopsy</strong> – Age-adjusted hypercellularity with panmyelosis (ie, increased erythroid, granulocytic, and megakaryocytic growth) and pleomorphic, mature megakaryocytes. Later phases of PV may exhibit variable levels of erythroid cellularity and/or increased fibrosis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>JAK2</em></strong><strong> mutation</strong> – <em>JAK2</em> V617F or exon 12 mutation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Minor criterion</strong> – Subnormal serum EPO</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – PV must be distinguished from (see <a class="local">'Differential diagnosis'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relative polycythemia</strong> – Elevated Hb/Hct due to intravascular volume contraction. (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Relative polycythemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary polycythemia</strong> – Hypoxia and/or elevated EPO due to cardiovascular, lung disease, kidney disorders, EPO-producing tumors, as described separately. (See  <a class="medical medical_review" href="/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Secondary polycythemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other MPNs</strong> – Essential thrombocythemia, chronic myeloid leukemia, primary myelofibrosis. (See <a class="local">'Essential thrombocythemia'</a> above.)</p><p></p><p class="headingAnchor" id="H3721613020"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003; 88:13.</a></li><li><a class="nounderline abstract_t">Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25:1048.</a></li><li><a class="nounderline abstract_t">Cario H, Schwarz K, Herter JM, et al. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol 2008; 142:622.</a></li><li><a class="nounderline abstract_t">Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12:339.</a></li><li><a class="nounderline abstract_t">Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27:1874.</a></li><li><a class="nounderline abstract_t">Anía BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994; 47:89.</a></li><li><a class="nounderline abstract_t">Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32:171.</a></li><li><a class="nounderline abstract_t">Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346.</a></li><li><a class="nounderline abstract_t">Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30:4098.</a></li><li><a class="nounderline abstract_t">Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118:401.</a></li><li><a class="nounderline abstract_t">Geyer H, Scherber R, Kosiorek H, et al. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol 2016; 34:151.</a></li><li><a class="nounderline abstract_t">Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol 1985; 13:91.</a></li><li><a class="nounderline abstract_t">Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 2010; 40:828.</a></li><li><a class="nounderline abstract_t">Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 2013; 88:665.</a></li><li><a class="nounderline abstract_t">Gangat N, Strand JJ, Lasho TL, et al. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 2008; 83:451.</a></li><li><a class="nounderline abstract_t">Steinman HK, Kobza-Black A, Lotti TM, et al. Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol 1987; 116:329.</a></li><li><a class="nounderline abstract_t">Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol 1987; 116:21.</a></li><li><a class="nounderline abstract_t">Fjellner B, Hägermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 1979; 59:505.</a></li><li><a class="nounderline abstract_t">Ishii T, Wang J, Zhang W, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 2009; 113:5942.</a></li><li><a class="nounderline abstract_t">Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23:441.</a></li><li><a class="nounderline abstract_t">van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23:357.</a></li><li><a class="nounderline abstract_t">Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80:1965.</a></li><li><a class="nounderline abstract_t">Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22:2020.</a></li><li><a class="nounderline abstract_t">Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013; 162:730.</a></li><li><a class="nounderline abstract_t">Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995; 55:315.</a></li><li><a class="nounderline abstract_t">De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.</a></li><li><a class="nounderline abstract_t">Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129:553.</a></li><li><a class="nounderline abstract_t">Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031.</a></li><li><a class="nounderline abstract_t">Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108:3223.</a></li><li><a class="nounderline abstract_t">Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528.</a></li><li><a class="nounderline abstract_t">Michiels JJ, van Genderen PJ, Jansen PH, Koudstaal PJ. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma 1996; 22 Suppl 1:65.</a></li><li><a class="nounderline abstract_t">Yang HS, Joe SG, Kim JG, et al. Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography. Br J Haematol 2013; 161:745.</a></li><li><a class="nounderline abstract_t">Torgano G, Mandelli C, Massaro P, et al. Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori. Br J Haematol 2002; 117:198.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li class="breakAll">Peterson P, Ellis JT. The bone marrow in polycythemia vera. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.31.</li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012; 119:2239.</a></li><li><a class="nounderline abstract_t">Najfeld V. FISHing among myeloproliferative disorders. Semin Hematol 1997; 34:55.</a></li><li class="breakAll">Pierre RV, Whang-Peng J. Cytogenetics. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman, LR, Berk, PD, Berlin, NI (Eds), WB Saunders, Philadelphia 1995. p.91.</li><li><a class="nounderline abstract_t">Westwood NB, Gruszka-Westwood AM, Pearson CE, et al. The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 2000; 110:839.</a></li><li><a class="nounderline abstract_t">Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002; 119:558.</a></li><li><a class="nounderline abstract_t">Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102:1869.</a></li><li><a class="nounderline abstract_t">Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 2005; 4:224.</a></li><li><a class="nounderline abstract_t">Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.</a></li><li><a class="nounderline abstract_t">Wang YL, Vandris K, Jones A, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2008; 22:1289.</a></li><li><a class="nounderline abstract_t">Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21:1960.</a></li><li><a class="nounderline abstract_t">Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363:1189.</a></li><li><a class="nounderline abstract_t">Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86:668.</a></li><li><a class="nounderline abstract_t">Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013.</a></li><li><a class="nounderline abstract_t">Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005; 42:206.</a></li><li><a class="nounderline abstract_t">Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131:166.</a></li><li><a class="nounderline abstract_t">Spivak JL. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 2010; 152:300.</a></li><li><a class="nounderline abstract_t">Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106:631.</a></li><li><a class="nounderline abstract_t">Dupont S, Massé A, James C, et al. The JAK2 617V&gt;F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110:1013.</a></li><li><a class="nounderline abstract_t">Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840.</a></li><li><a class="nounderline abstract_t">Silver RT, Vandris K, Wang YL, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011; 35:177.</a></li><li><a class="nounderline abstract_t">Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138:354.</a></li><li><a class="nounderline abstract_t">Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108:2435.</a></li><li><a class="nounderline abstract_t">Scott LM, Beer PA, Bench AJ, et al. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007; 139:511.</a></li><li><a class="nounderline abstract_t">Butcher CM, Hahn U, To LB, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008; 22:870.</a></li><li><a class="nounderline abstract_t">Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117:2813.</a></li><li><a class="nounderline abstract_t">Colaizzo D, Amitrano L, Tiscia GL, et al. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007; 110:2768.</a></li><li><a class="nounderline abstract_t">Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111:1686.</a></li><li><a class="nounderline abstract_t">Messinezy M, Westwood NB, Woodcock SP, et al. Low serum erythropoietin--a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol 1995; 17:217.</a></li><li><a class="nounderline abstract_t">Birgegård G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992; 81:603.</a></li><li><a class="nounderline abstract_t">Cotes PM, Doré CJ, Yin JA, et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986; 315:283.</a></li><li><a class="nounderline abstract_t">Najean Y, Schlageter MH, Toubert ME, Podgorniak MP. Radioimmunoassay of immunoreactive erythropoietin as a clinical tool for the classification of polycythaemias. Nouv Rev Fr Hematol 1990; 32:237.</a></li><li><a class="nounderline abstract_t">Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica 1997; 82:406.</a></li><li><a class="nounderline abstract_t">Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117:47.</a></li><li><a class="nounderline abstract_t">Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer 2005; 104:213.</a></li><li><a class="nounderline abstract_t">Fairbanks VF. Myeloproliferative Disease: Polycythemia Vera: The Packed Cell Volume and The Curious Logic of The Red Cell Mass. Hematology 2000; 4:381.</a></li><li><a class="nounderline abstract_t">Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748.</a></li><li><a class="nounderline abstract_t">Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996; 22 Suppl 1:87.</a></li><li><a class="nounderline abstract_t">Alvarez-Larrán A, Ancochea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012; 97:1704.</a></li><li><a class="nounderline abstract_t">Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed? Nouv Rev Fr Hematol 1994; 36:151.</a></li><li><a class="nounderline abstract_t">Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005; 129:701.</a></li><li><a class="nounderline abstract_t">Shih LY, Lee CT, See LC, et al. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. Eur J Clin Invest 1998; 28:569.</a></li><li><a class="nounderline abstract_t">Weinberg RS, Worsley A, Gilbert HS, et al. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk Res 1989; 13:331.</a></li><li><a class="nounderline abstract_t">Zwicky C, Theiler L, Zbären K, et al. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol 2002; 117:598.</a></li><li><a class="nounderline abstract_t">Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122:1881.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014; 89:199.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014; 89:52.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol 2014; 89:588.</a></li><li><a class="nounderline abstract_t">Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112:231.</a></li><li><a class="nounderline abstract_t">Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092.</a></li><li><a class="nounderline abstract_t">Tefferi A. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. N Engl J Med 2007; 356:444.</a></li><li><a class="nounderline abstract_t">Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc 2007; 82:599.</a></li><li><a class="nounderline abstract_t">Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009; 6:627.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007; 138:821.</a></li><li><a class="nounderline abstract_t">McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130:174.</a></li><li><a class="nounderline abstract_t">Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.</a></li><li><a class="nounderline abstract_t">Dainiak N, Hoffman R, Lebowitz AI, et al. Erythropoietin-dependent primary pure erythrocytosis. Blood 1979; 53:1076.</a></li><li><a class="nounderline abstract_t">Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.</a></li></ol></div><div id="topicVersionRevision">Topic 4517 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12551821" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17369568" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557746" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1198126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and classification of the polycythemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739289" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092146" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16673273" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537803" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071245" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536863" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598745" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2411768" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aquagenic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20597963" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Polycythemia vera-associated pruritus and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23657863" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3567071" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3814512" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/94209" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196660" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387203" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erythromelalgia and vascular complications in polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9263352" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327286" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18800144" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855810" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Splanchnic vein thrombosis in myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7493678" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387199" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877740" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16762626" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17057021" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133457" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951774" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23496285" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918555" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918555" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918555" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22246040" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025163" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : FISHing among myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025163" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : FISHing among myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054066" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406101" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730106" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15865876" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Karyotype and molecular cytogenetic studies in polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267906" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079740" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : JAK2 Mutations are present in all cases of polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597810" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843259" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : LNK mutations in JAK2 mutation-negative erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674578" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The JAK2 exon 12 mutations: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210034" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Polycythemia vera: scientific advances and current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197445" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194236" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369984" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389763" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The JAK2 617V&gt;F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17379742" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650526" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614822" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772604" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910642" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914411" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224469" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17881638" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984312" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8719893" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Low serum erythropoietin--a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1390249" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3724821" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2290709" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Radioimmunoassay of immunoreactive erythropoietin as a clinical tool for the classification of polycythaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299851" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918532" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889449" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399580" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Myeloproliferative Disease: Polycythemia Vera: The Packed Cell Volume and The Curious Logic of The Red Cell Mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7772511" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951778" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The diagnostic criteria of polycythaemia rubra vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689671" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036131" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15916693" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726038" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2716348" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12028027" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900239" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166817" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Masked polycythemia vera diagnosed according to WHO and BCSH classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996471" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Masked polycythemia vera (mPV): results of an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24535932" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18401028" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488875" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267904" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493421" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19806146" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17672880" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029446" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1954391" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/444659" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Erythropoietin-dependent primary pure erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192789" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
